Genentech takes the health and safety of our patients, customers, employees, and local communities very seriously, and we are actively responding to the global COVID-19 pandemic. For more information, please visit our COVID-19 response page.
The below Genentech/Roche-sponsored congress posters and oral presentations include data presented at scientific meetings from mid-2019 onwards. Click the below links for congress publications of interest.
Final analysis of the STASEY trial: a single-arm, multicenter, open-label, Phase III clinical trial evaluating the safety and tolerability of emicizumab prophylaxis in persons with hemophilia A with factor VIII inhibitors
A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): Interim analysis results
A randomized, multicenter, open-label, Phase III clinical trial to evaluate the efficacy, safety, and pharmacokinetics of prophylactic emicizumab versus no prophylaxis in persons with hemophilia A in the Asia-Pacific region (HAVEN 5)
Wang S, Zhao X, Wang X, et al. Poster presentation PB0957.
Second interim analysis results from the STASEY trial: A single-arm, multicenter, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in people with hemophilia A (PwHA) with FVIII inhibitors.